Quarter
Charts

ImmuCell Corporation

ICCC

CIK 0000811641 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$8M
↓-1.6% -$125Kvs FY2024 (Q4)
Operating Income
$1M
↑+7.3% +$99Kvs FY2024 (Q4)
Net Income
$1M
↑+10.9% +$131Kvs FY2024 (Q4)
Gross Profit
$3M
↑+2.8% +$79Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
55/100
  • Profitability
    0ROIC 3.6% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 4.26 (above 1.5 = solid)
  • Leverage
    83D/E 0.34 (under 0.5 = conservative)
  • Efficiency
    33Asset Turnover 0.63x (1.0+ = capital-efficient)
  • Growth
    11Revenue YoY -1.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 0.4% · trend +20.7pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project ICCC's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$2.33
Total enterprise IV
$21M
Diluted shares
0.01B
Terminal PV
$15M (72% of total)
Year-5 FCF
$2M
YearProjected FCFDiscounted PV
+1$1M$1M
+2$1M$1M
+3$2M$1M
+4$2M$1M
+5$2M$1M
Terminal$25M$15M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$1M
investment in PP&E
Stock-based comp (TTM)
$296K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$43M
everything owned
Total liabilities
$15M
everything owed
Stockholders' equity
$27M
shareholder claim
Net debt
$5M
LT debt minus cash

Recent performance · 63 quarters

Revenue↓-1.6% -$125K
$8M
Net Income↑+80.1% +$562K
$-140K
Free Cash Flow↑+258.1% +$506K
$310K
Operating Margin↑+9.9pts
0.4%

Drill down

ICCC Sankey

See ImmuCell Corporation's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

ICCC Charts

63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

ICCC Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics